Drugs have been created targeting CD133 including targeted toxins (C178ABC-CD133Mab, dEpCAMCD133KDEL, CD133NPs, dCD133KDEL) [22–25] and BiKEs (CD16133) [4] showing high efficacy in tumor elimination in vitro and in vivo even in tumors with only a small number of CD133-expressing cells. This evidence concerns the gene PROM1 and neoplasm.